Arbutus Biopharma Corp: Form 10-Q for the period ended Sep 30, 2017
Filed with the SEC on Nov 2, 2017 and accepted by EDGAR at Nov 2, 2017, 17:23 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2017-07-01 to 2017-09-30 | $6.9m | us-gaap:Revenues |
| Revenue | 9 months2017-01-01 to 2017-09-30 | $8.2m | us-gaap:Revenues |
| Research and development | 3 months2017-07-01 to 2017-09-30 | $15.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2017-01-01 to 2017-09-30 | $44.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2017-07-01 to 2017-09-30 | −$12.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2017-01-01 to 2017-09-30 | −$50.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2017-07-01 to 2017-09-30 | $76.0k | us-gaap:InterestExpense |
| Interest expense | 9 months2017-01-01 to 2017-09-30 | $186.0k | us-gaap:InterestExpense |
| Income tax | 3 months2017-07-01 to 2017-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2017-01-01 to 2017-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2017-07-01 to 2017-09-30 | −$11.6m | us-gaap:NetIncomeLoss |
| Net income | 9 months2017-01-01 to 2017-09-30 | −$48.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2017-07-01 to 2017-09-30 | −$0.21 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months2017-01-01 to 2017-09-30 | −$0.89 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 3 months2017-07-01 to 2017-09-30 | −$15.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Operating cash flow | 9 months2017-01-01 to 2017-09-30 | −$38.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2017-07-01 to 2017-09-30 | $538.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Capital expenditure | 9 months2017-01-01 to 2017-09-30 | $7.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2017-09-30 | $15.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-09-30 | $90.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2017-09-30 | $239.8m | us-gaap:Assets |
| Current liabilities | At period end2017-09-30 | $8.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2017-09-30 | $72.5m | us-gaap:Liabilities |
| Shareholders' equity | At period end2017-09-30 | $167.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-17-010727. Last ingested by Listed: Nov 12, 2026, 17:55 ET. Listed shows no prices and gives no investment advice.